---
figid: PMC4229029__nihms352986f1
figlink: /pmc/articles/PMC4229029/figure/F1/
number: F1
caption: A. Extracellular growth factors bind with cell receptors, activating a series
  of intricately regulated signaling. Tumor cells retain some levels of feedback inhibition,
  activation of one pathway might lead to inhibition of upstream substrates within
  the pathway, and/or the inhibition of compensatory pathways. Tumor cells depend
  on certain oncogenes for growth (“oncogene addiction”), these oncogene products
  provide good targets for molecularly targeted therapies. B. Molecular inhibitors
  suppress the overactivated growth/survival pathway, therefore tumors shrink. C.
  After prolonged treatment, induction of growth/survival signals of the same pathway
  and/or compensatory pathways leads to resistance against molecular inhibitors, which
  might be due to the disrupted feedback inhibitions. +++, overactivated signaling.
pmcid: PMC4229029
papertitle: 'Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale
  for Combination Therapy in Malignant Melanoma.'
reftext: S. Wu, et al. Curr Mol Med. ;11(7):553-563.
pmc_ranked_result_index: '58231'
pathway_score: 0.9272282
filename: nihms352986f1.jpg
figtitle: 'Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale
  for Combination Therapy in Malignant Melanoma'
year: ''
organisms:
- Homo sapiens
ndex: 361c4986-df07-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4229029__nihms352986f1.html
  '@type': Dataset
  description: A. Extracellular growth factors bind with cell receptors, activating
    a series of intricately regulated signaling. Tumor cells retain some levels of
    feedback inhibition, activation of one pathway might lead to inhibition of upstream
    substrates within the pathway, and/or the inhibition of compensatory pathways.
    Tumor cells depend on certain oncogenes for growth (“oncogene addiction”), these
    oncogene products provide good targets for molecularly targeted therapies. B.
    Molecular inhibitors suppress the overactivated growth/survival pathway, therefore
    tumors shrink. C. After prolonged treatment, induction of growth/survival signals
    of the same pathway and/or compensatory pathways leads to resistance against molecular
    inhibitors, which might be due to the disrupted feedback inhibitions. +++, overactivated
    signaling.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - PIK3R5
  - AKT2
  - PIK3CB
  - AKT3
  - PIK3CA
  - MTOR
  - RAF1
  - EGFR
  - MAP2K2
  - PIK3R6
  - MAPK3
  - PDGFRB
  - PIK3CG
  - MAPK1
  - BRAF
  - PIK3CD
  - PIK3R4
  - KRAS
  - PDGFRA
  - PIK3R3
  - KIT
  - ARAF
  - HRAS
  - NRAS
  - MAP2K1
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: c-KIT
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4229029__F1
redirect_from: /figures/PMC4229029__F1
figtype: Figure
---
